Effect of maternal high dosages of folic acid supplements on neurocognitive development in children at 4-5 y of age: the prospective birth cohort Infancia y Medio Ambiente (INMA) study

The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain development in offspring are well known. There is concern, however, about the long-term effects of the maternal use of high dosages of FASs that exceed...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The American journal of clinical nutrition Ročník 106; číslo 3; s. 878
Hlavní autori:	Valera-Gran, Desirée, Navarrete-Muñoz, Eva M, Garcia de la Hera, Manuela, Fernández-Somoano, Ana, Tardón, Adonina, Ibarluzea, Jesús, Balluerka, Nekane, Murcia, Mario, González-Safont, Llúcia, Romaguera, Dora, Julvez, Jordi, Vioque, Jesús
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.09.2017
Predmet:	Adult Brain - drug effects Child Development - drug effects Child, Preschool Cognition - drug effects Diet Diet Surveys Dietary Supplements - adverse effects Female Folic Acid - administration & dosage Folic Acid - adverse effects Humans Male Memory - drug effects Pregnancy Prenatal Exposure Delayed Effects Prenatal Nutritional Physiological Phenomena Prospective Studies Spain Vitamin B Complex - administration & dosage Vitamin B Complex - adverse effects child neurocognitive development folate folic acid supplements periconception period pregnancy
ISSN:	1938-3207, 1938-3207
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain development in offspring are well known. There is concern, however, about the long-term effects of the maternal use of high dosages of FASs that exceed the Tolerable Upper Intake Level (UL) (≥1000 μg/d) on child neurocognitive outcomes. The objective of the study was to examine the association between the use of high dosages of FASs during pregnancy and child neuropsychological development at ages 4-5 y. The multicenter prospective mother-child cohort study, the Infancia y Medio Ambiente (INMA) Project, was conducted in 4 regions of Spain: Asturias, Sabadell, Gipuzkoa, and Valencia. Pregnant women were recruited between 2003 and 2008. Data on 1682 mother-child pairs were included in the final analyses. The pregnant women completed an interviewer-administered questionnaire that was validated to estimate typical dietary folate intake and the use of FASs at 10-13 and 28-32 wk of gestation. Neuropsychological development scores at 4-5 y of age were estimated with the use of the McCarthy Scales of Children's Abilities. Multiple linear regression and meta-analysis were used to obtain combined-effect estimates. During the periconception period, one-third of the women ( = 502) took FAS dosages ≥1000 μg/d. The use of FAS dosages ≥1000 μg/d in this period was negatively associated with several neuropsychological outcomes scores in children: global verbal (β = -2.49; 95% CI: -4.71, -0.27), verbal memory (β = -3.59; 95% CI: -6.95, -0.23), cognitive function of posterior cortex (β = -2.31; 95% CI: -4.45, -0.18), and cognitive function of left posterior cortex (β = -3.26; 95% CI: -5.51, -1.01). The use of FAS dosages exceeding the UL (≥1000 μg/d) during the periconception period was associated with lower levels of cognitive development in children aged 4-5 y. The use of FAS dosages ≥1000 μg/d during pregnancy should be monitored and prevented as much as possible, unless medically prescribed.
AbstractList	Background: The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain development in offspring are well known. There is concern, however, about the long-term effects of the maternal use of high dosages of FASs that exceed the Tolerable Upper Intake Level (UL) (≥1000 μg/d) on child neurocognitive outcomes.Objective: The objective of the study was to examine the association between the use of high dosages of FASs during pregnancy and child neuropsychological development at ages 4-5 y.Design: The multicenter prospective mother-child cohort study, the Infancia y Medio Ambiente (INMA) Project, was conducted in 4 regions of Spain: Asturias, Sabadell, Gipuzkoa, and Valencia. Pregnant women were recruited between 2003 and 2008. Data on 1682 mother-child pairs were included in the final analyses. The pregnant women completed an interviewer-administered questionnaire that was validated to estimate typical dietary folate intake and the use of FASs at 10-13 and 28-32 wk of gestation. Neuropsychological development scores at 4-5 y of age were estimated with the use of the McCarthy Scales of Children's Abilities. Multiple linear regression and meta-analysis were used to obtain combined-effect estimates.Results: During the periconception period, one-third of the women (n = 502) took FAS dosages ≥1000 μg/d. The use of FAS dosages ≥1000 μg/d in this period was negatively associated with several neuropsychological outcomes scores in children: global verbal (β = -2.49; 95% CI: -4.71, -0.27), verbal memory (β = -3.59; 95% CI: -6.95, -0.23), cognitive function of posterior cortex (β = -2.31; 95% CI: -4.45, -0.18), and cognitive function of left posterior cortex (β = -3.26; 95% CI: -5.51, -1.01).Conclusions: The use of FAS dosages exceeding the UL (≥1000 μg/d) during the periconception period was associated with lower levels of cognitive development in children aged 4-5 y. The use of FAS dosages ≥1000 μg/d during pregnancy should be monitored and prevented as much as possible, unless medically prescribed.Background: The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain development in offspring are well known. There is concern, however, about the long-term effects of the maternal use of high dosages of FASs that exceed the Tolerable Upper Intake Level (UL) (≥1000 μg/d) on child neurocognitive outcomes.Objective: The objective of the study was to examine the association between the use of high dosages of FASs during pregnancy and child neuropsychological development at ages 4-5 y.Design: The multicenter prospective mother-child cohort study, the Infancia y Medio Ambiente (INMA) Project, was conducted in 4 regions of Spain: Asturias, Sabadell, Gipuzkoa, and Valencia. Pregnant women were recruited between 2003 and 2008. Data on 1682 mother-child pairs were included in the final analyses. The pregnant women completed an interviewer-administered questionnaire that was validated to estimate typical dietary folate intake and the use of FASs at 10-13 and 28-32 wk of gestation. Neuropsychological development scores at 4-5 y of age were estimated with the use of the McCarthy Scales of Children's Abilities. Multiple linear regression and meta-analysis were used to obtain combined-effect estimates.Results: During the periconception period, one-third of the women (n = 502) took FAS dosages ≥1000 μg/d. The use of FAS dosages ≥1000 μg/d in this period was negatively associated with several neuropsychological outcomes scores in children: global verbal (β = -2.49; 95% CI: -4.71, -0.27), verbal memory (β = -3.59; 95% CI: -6.95, -0.23), cognitive function of posterior cortex (β = -2.31; 95% CI: -4.45, -0.18), and cognitive function of left posterior cortex (β = -3.26; 95% CI: -5.51, -1.01).Conclusions: The use of FAS dosages exceeding the UL (≥1000 μg/d) during the periconception period was associated with lower levels of cognitive development in children aged 4-5 y. The use of FAS dosages ≥1000 μg/d during pregnancy should be monitored and prevented as much as possible, unless medically prescribed. The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain development in offspring are well known. There is concern, however, about the long-term effects of the maternal use of high dosages of FASs that exceed the Tolerable Upper Intake Level (UL) (≥1000 μg/d) on child neurocognitive outcomes. The objective of the study was to examine the association between the use of high dosages of FASs during pregnancy and child neuropsychological development at ages 4-5 y. The multicenter prospective mother-child cohort study, the Infancia y Medio Ambiente (INMA) Project, was conducted in 4 regions of Spain: Asturias, Sabadell, Gipuzkoa, and Valencia. Pregnant women were recruited between 2003 and 2008. Data on 1682 mother-child pairs were included in the final analyses. The pregnant women completed an interviewer-administered questionnaire that was validated to estimate typical dietary folate intake and the use of FASs at 10-13 and 28-32 wk of gestation. Neuropsychological development scores at 4-5 y of age were estimated with the use of the McCarthy Scales of Children's Abilities. Multiple linear regression and meta-analysis were used to obtain combined-effect estimates. During the periconception period, one-third of the women ( = 502) took FAS dosages ≥1000 μg/d. The use of FAS dosages ≥1000 μg/d in this period was negatively associated with several neuropsychological outcomes scores in children: global verbal (β = -2.49; 95% CI: -4.71, -0.27), verbal memory (β = -3.59; 95% CI: -6.95, -0.23), cognitive function of posterior cortex (β = -2.31; 95% CI: -4.45, -0.18), and cognitive function of left posterior cortex (β = -3.26; 95% CI: -5.51, -1.01). The use of FAS dosages exceeding the UL (≥1000 μg/d) during the periconception period was associated with lower levels of cognitive development in children aged 4-5 y. The use of FAS dosages ≥1000 μg/d during pregnancy should be monitored and prevented as much as possible, unless medically prescribed.
Author	Tardón, Adonina Navarrete-Muñoz, Eva M González-Safont, Llúcia Ibarluzea, Jesús Romaguera, Dora Balluerka, Nekane Vioque, Jesús Valera-Gran, Desirée Fernández-Somoano, Ana Murcia, Mario Julvez, Jordi Garcia de la Hera, Manuela
Author_xml	– sequence: 1 givenname: Desirée surname: Valera-Gran fullname: Valera-Gran, Desirée organization: Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain – sequence: 2 givenname: Eva M surname: Navarrete-Muñoz fullname: Navarrete-Muñoz, Eva M organization: Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain – sequence: 3 givenname: Manuela surname: Garcia de la Hera fullname: Garcia de la Hera, Manuela organization: Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain – sequence: 4 givenname: Ana surname: Fernández-Somoano fullname: Fernández-Somoano, Ana organization: Department of Preventive Medicine and Public Health, University of Oviedo, Oviedo, Spain – sequence: 5 givenname: Adonina surname: Tardón fullname: Tardón, Adonina organization: Department of Preventive Medicine and Public Health, University of Oviedo, Oviedo, Spain – sequence: 6 givenname: Jesús surname: Ibarluzea fullname: Ibarluzea, Jesús organization: Health Research Institute (BIODONOSTIA), San Sebastian, Spain – sequence: 7 givenname: Nekane surname: Balluerka fullname: Balluerka, Nekane organization: Department of Social Psychology and Behavioral Sciences Methods, University of the Basque Country, San Sebastian, Spain – sequence: 8 givenname: Mario surname: Murcia fullname: Murcia, Mario organization: FISABIO-University of Valencia-University Jaume I Joint Research Unit of Epidemiology and Environmental Health, Valencia, Spain – sequence: 9 givenname: Llúcia surname: González-Safont fullname: González-Safont, Llúcia organization: FISABIO-University of Valencia-University Jaume I Joint Research Unit of Epidemiology and Environmental Health, Valencia, Spain – sequence: 10 givenname: Dora surname: Romaguera fullname: Romaguera, Dora organization: Spanish Consortium for Research on Obesity and Nutrition (CIBEROBN), Madrid, Spain – sequence: 11 givenname: Jordi surname: Julvez fullname: Julvez, Jordi organization: ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; and – sequence: 12 givenname: Jesús orcidid: 0000-0002-2284-148X surname: Vioque fullname: Vioque, Jesús email: vioque@umh.es organization: Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28724645$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEFv2zAMhYWiRdN2Pfc28NgdnEqyLdu7BUHXBmi3y3YOaJmKFdiSZ8kB8s_68-agHdATCbzHj4-8ZufOO2LsTvBlWmX5A-61WwpRLEUuC1WdsStRpWWSSl6cf-oX7DqEPedCZqW6ZAtZFjJTWX7F3h6NIR3BG-gx0uiwg9buWmh8wB2Fk2B8ZzWgtg2EaRg66snFWXHgaBq99jtnoz0QNHSgzg8nGawD3dquGckBRsiSHI4n2Az9DrElGEYfhnn1abC2Y2xB-9aPETbOoNMWZ_8rNdbDqq_tjCS43_x8XX2DEKfm-IVdGOwC3X7UG_bnx-Pv9XPy8utps169JDoXeUyonE-WtSaFEktjRGpUyjMuFemClCTkGVJVcSVL5KhQ5XWhdKnKvOKpauQNu3_nznn_ThTitrdBU9ehIz-FraikELJIRTFbv35Yp7qnZjuMtsfxuP3_bfkP_jeFVg
CitedBy_id	crossref_primary_10_1017_S0029665118002689 crossref_primary_10_3390_nu12061716 crossref_primary_10_3390_nu15214699 crossref_primary_10_1002_epd2_70097 crossref_primary_10_3390_ijms22115759 crossref_primary_10_1111_epi_18575 crossref_primary_10_1055_s_0043_1769001 crossref_primary_10_1039_D3FO03735E crossref_primary_10_1016_j_tem_2021_04_001 crossref_primary_10_46332_aemj_1530372 crossref_primary_10_1016_j_biochi_2020_04_019 crossref_primary_10_1007_s12031_018_1237_5 crossref_primary_10_1016_j_jns_2025_123627 crossref_primary_10_1016_j_ibneur_2024_12_009 crossref_primary_10_1093_nutrit_nuy025 crossref_primary_10_1016_j_jnutbio_2020_108554 crossref_primary_10_1093_humrep_dez036 crossref_primary_10_3390_ijms22020927 crossref_primary_10_1016_j_gaceta_2018_07_014 crossref_primary_10_1111_joim_13279 crossref_primary_10_3390_nu14010066 crossref_primary_10_1016_j_schres_2021_03_008 crossref_primary_10_1016_j_brainres_2023_148639 crossref_primary_10_1038_s41430_025_01652_8 crossref_primary_10_1111_mcn_13589 crossref_primary_10_1016_j_clnu_2024_04_007 crossref_primary_10_3390_nu15194303 crossref_primary_10_1212_CON_0000000000000713 crossref_primary_10_1038_s41538_025_00396_w crossref_primary_10_3390_cells10061536 crossref_primary_10_3390_ijms23168916 crossref_primary_10_3390_ijerph191912123 crossref_primary_10_31083_j_jin2301015 crossref_primary_10_3390_antiox13040453 crossref_primary_10_3390_ijerph16183440 crossref_primary_10_1038_s41430_020_0612_9 crossref_primary_10_1111_and_14400 crossref_primary_10_1080_10408398_2018_1549017 crossref_primary_10_1016_j_brainresbull_2021_11_008 crossref_primary_10_1016_j_pnpbp_2019_109650 crossref_primary_10_1093_ije_dyz197 crossref_primary_10_3390_biom12020197 crossref_primary_10_1017_S1368980018003610 crossref_primary_10_1007_s10815_025_03613_3 crossref_primary_10_1093_nutrit_nuy047 crossref_primary_10_1016_j_ajcnut_2023_04_026 crossref_primary_10_1080_10408398_2021_1993781 crossref_primary_10_1002_mnfr_202100197 crossref_primary_10_3390_brainsci7110149 crossref_primary_10_1016_j_tem_2021_05_011 crossref_primary_10_1093_ajcn_nqac048 crossref_primary_10_1016_j_clnesp_2024_06_006 crossref_primary_10_3390_nu13020327 crossref_primary_10_1038_s42003_023_05492_9 crossref_primary_10_1016_j_jad_2024_09_105 crossref_primary_10_1007_s00394_017_1588_7 crossref_primary_10_1155_2022_9540701
ContentType	Journal Article
Copyright	2017 American Society for Nutrition.
Copyright_xml	– notice: 2017 American Society for Nutrition.
CorporateAuthor	INMA Project
CorporateAuthor_xml	– name: INMA Project
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.3945/ajcn.117.152769
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Diet & Clinical Nutrition
EISSN	1938-3207
ExternalDocumentID	28724645
Genre	Multicenter Study Journal Article
GroupedDBID	--- -ET -~X ..I .55 .GJ 0R~ 1HT 23M 2FS 2WC 3O- 4.4 48X 53G 5GY 5RE 5VS 6J9 85S 8R4 8R5 A8Z AABZA AACZT AAGQS AAHBH AAIKC AAJQQ AALRI AAMNW AAPGJ AAPQZ AAUQX AAUTI AAVAP AAWDT AAWTL AAXUO AAYOK ABBTP ABDNZ ABDPE ABJNI ABLJU ABOCM ABPTD ABSAR ABWST ACFRR ACGFO ACGFS ACGOD ACNCT ACPRK ACPVT ACUFI ACUTJ ADBBV ADGZP ADHUB ADRTK ADUKH ADVEK ADVLN AEGXH AENEX AETBJ AFFDN AFFNX AFFZL AFJKZ AFOFC AFRAH AFXAL AGINJ AGKRT AGNAY AGQXC AGUTN AHMBA AI. AIAGR AITUG AJEEA AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ANFBD AQDSO AQKUS BAWUL BAYMD BCRHZ BKOMP BTRTY C1A CDBKE CGR CUY CVF DAKXR DIK E3Z EBS ECM EIF EIHJH EJD ENERS EX3 F5P F9R FDB FECEO FLUFQ FOEOM FOTVD FQBLK FRP GAUVT GJXCC GX1 H13 HF~ HZ~ IH2 J5H KBUDW KOP KQ8 KSI KSN L7B LPU MBLQV MHKGH MV1 MVM N4W NEJ NHB NHCRO NOMLY NOYVH NPM NVLIB O9- ODMLO OHT OK1 OVD P2P P6G PCD PQQKQ PRG Q2X R0Z RHF RHI RNS ROL ROX SJN SV3 TCN TEORI TMA TNT TR2 TWZ UBH UHB UKR VH1 VXZ W2D W8F WH7 WHG WOQ WOW X7M XOL XSW YBU YHG YOJ YQJ YR5 YRY YSK YV5 YYQ YZZ Z5M ZCA ZCG ZGI ZUP ZXP ~KM 7X8 ABUFD ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS
ID	FETCH-LOGICAL-c515t-e82482bce6a2a8ff13f6304026ec7e62ea04ae990628a0a6a65b76c86859036d2
IEDL.DBID	7X8
ISICitedReferencesCount	64
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000408890000021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1938-3207
IngestDate	Sun Nov 09 11:25:22 EST 2025 Wed Feb 19 02:25:36 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	child neurocognitive development folate folic acid supplements periconception period pregnancy
Language	English
License	2017 American Society for Nutrition.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c515t-e82482bce6a2a8ff13f6304026ec7e62ea04ae990628a0a6a65b76c86859036d2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-2284-148X
OpenAccessLink	https://academic.oup.com/ajcn/article-pdf/106/3/878/23803201/ajcn152769.pdf
PMID	28724645
PQID	1921127317
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1921127317 pubmed_primary_28724645
PublicationCentury	2000
PublicationDate	2017-09-01
PublicationDateYYYYMMDD	2017-09-01
PublicationDate_xml	– month: 09 year: 2017 text: 2017-09-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	The American journal of clinical nutrition
PublicationTitleAlternate	Am J Clin Nutr
PublicationYear	2017
SSID	ssj0012486
Score	2.4989681
Snippet	The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain development... Background: The benefits of the use of folic acid supplements (FASs) during the periconception period to prevent neural tube defects and to ensure normal brain...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	878
SubjectTerms	Adult Brain - drug effects Child Development - drug effects Child, Preschool Cognition - drug effects Diet Diet Surveys Dietary Supplements - adverse effects Female Folic Acid - administration & dosage Folic Acid - adverse effects Humans Male Memory - drug effects Pregnancy Prenatal Exposure Delayed Effects Prenatal Nutritional Physiological Phenomena Prospective Studies Spain Vitamin B Complex - administration & dosage Vitamin B Complex - adverse effects
Title	Effect of maternal high dosages of folic acid supplements on neurocognitive development in children at 4-5 y of age: the prospective birth cohort Infancia y Medio Ambiente (INMA) study
URI	https://www.ncbi.nlm.nih.gov/pubmed/28724645 https://www.proquest.com/docview/1921127317
Volume	106
WOSCitedRecordID	wos000408890000021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nj9QwDI2ARWgvfCywDF8yEkJwiHaapknLBY2AFXuYag8gzW3kpKm2CNplWpD4Z_w87LRlbgiJSy9po1R27dfYeU-I5-xDqcucNGpppUadSLQKZeEybwOSWdwoNmHLMt9sivNpw62f2irnmBgDddV53iM_Yd6uhHJtYt9cfpOsGsXV1UlC46o4SAnKsFfbzb6KoHRUeiSMksuU1jJS-6SFzk7ws2-5YMn6P9b8BV_GPHN6639XeFvcnBAmrEaXuCOuhPZILN41YYAXMNGAfoFyZuE_EjfWU339rvg1khlDVwMh2UgPDUxoDFXHDWg9D9TMJAzomwp6lgSN-4s00kLkxvzTjwTVvh8JmhbmY-OAA2iZwU-ejCZ9DYRBgd51PvQJrtkNF8DSvbsBzto6UoLQ_bzODlZfHZ_hDPDyrFyvXkEkyL0nPp2-__j2g5y0HaQnBDXIkJNxlPPBoMK8rpO0NikFFGUC-YhR5CYaQ8Esyjku0aDJnDU-N3lWUNKt1H1xre3a8EDA0qW6QrSJTlBbl2IwAXPj6NfbV5j6hXg222tL3w4XRLAN3fd-u7fYQhyPRt9ejiQfW_qTVFz1ffgPTz8Sh4qzfWw9eywOaooc4Ym47n8MTb97Gp2SruX5-je4We13
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+maternal+high+dosages+of+folic+acid+supplements+on+neurocognitive+development+in+children+at+4-5+y+of+age%3A+the+prospective+birth+cohort+Infancia+y+Medio+Ambiente+%28INMA%29+study&rft.jtitle=The+American+journal+of+clinical+nutrition&rft.au=Valera-Gran%2C+Desir%C3%A9e&rft.au=Navarrete-Mu%C3%B1oz%2C+Eva+M&rft.au=Garcia+de+la+Hera%2C+Manuela&rft.au=Fern%C3%A1ndez-Somoano%2C+Ana&rft.date=2017-09-01&rft.issn=1938-3207&rft.eissn=1938-3207&rft.volume=106&rft.issue=3&rft.spage=878&rft_id=info:doi/10.3945%2Fajcn.117.152769&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1938-3207&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1938-3207&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1938-3207&client=summon